Welcome to our dedicated page for DBV Technologies S.A. SEC filings (Ticker: DBVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DBV Technologies S.A. filings document the disclosure record of a French late-stage biopharmaceutical issuer with American Depositary Shares listed under DBVT. The filings identify ordinary shares and ADSs, with each ADS representing five ordinary shares, and cover the company’s VIASKIN patch technology, epicutaneous immunotherapy approach, and food-allergy development programs.
Recent SEC materials include Form 8-K reports for operating results, business highlights, clinical-data releases for the Phase 3 VITESSE study, warrant-related financing events, and governance matters. Proxy materials describe shareholder meeting proposals, board and committee matters, executive compensation, and equity-award plans.
DBV Technologies, a clinical-stage biopharma company focused on food allergies, highlights a defining year led by positive topline Phase 3 VITESSE results for the VIASKIN® Peanut Patch in children aged 4 to 7 years. These data support a planned Biologics License Application submission in the United States in the first half of the year and underpin preparations for potential commercialization.
The company is also advancing the COMFORT Toddlers safety trial in children aged 1 to 3 years and THRIVE, a first-of-its-kind study in infants aged 6 to 12 months. DBV reports raising $386.2 million in capital between March 2025 and January 2026, providing funding into the second quarter of 2027, including the potential U.S. launch of the VIASKIN Peanut Patch.
The proxy statement convenes the 2026 Annual Combined General Meeting on June 3, 2026 in Châtillon, France, with 40 resolutions covering approval of 2025 financial statements, director elections and compensation, share buyback and cancellation authority, extensive capital-raising and merger/de-merger authorizations, equity incentive plans, and bylaw amendments such as setting the CEO age limit at 70 years.
DBV Technologies S.A. adopted a new 2026 Performance Share Unit Plan and granted its CEO, Daniel Tassé, 1,740,000 Performance Share Units (PSUs) effective May 5, 2026. Each PSU is a conditional right to receive one ordinary share.
Half of the PSUs depend on each of two performance conditions tied to U.S. FDA acceptance for review or approval of biologics license applications for Viaskin Peanut, plus a continued employment requirement through July 1, 2028. Unmet PSUs by that date are forfeited. Vested shares are scheduled for delivery in four installments from July 1, 2028 through January 1, 2030, with change-in-control, death, disability, qualifying retirement and certain terminations receiving tailored treatment under the Plan, including potential cash settlement if the CEO is not a French tax resident.
DBV Technologies S.A. Schedule 13G/A amendment shows institutional holders led by Invus entities reporting beneficial ownership stakes in the issuer. Invus Public Equities beneficially held 17,997,870 ordinary shares as of March 31, 2026, representing 6.1% of the class. The filing states 296,042,447 shares outstanding as of March 25, 2026 (source: the issuer's Form 10-K).
The filing aggregates related parties and control links: Invus PE Advisors, Global Management, Siren, Avicenna entities, Ulys, and Raymond Debbane are disclosed as reporting persons or controlling entities; Mr. Debbane is the signing reporting person.
DBV Technologies S.A. filed a proxy statement for its 2026 Annual Combined General Meeting to be held on June 3, 2026 in Châtillon, France and webcast live. The letter from management highlights positive topline results from the Phase 3 VITESSE trial of the VIASKIN® Peanut Patch in children 4–7 and plans to submit a Biologics License Application in the United States in the first half of 2026. Management reports initiation and progress on supplemental pediatric trials including COMFORT Toddlers and THRIVE in infants. The company raised $386.2 million between March 2025 and January 2026 and states this funding supports operations into the second quarter of 2027. Proxy materials, the 2025 Form 10-K, meeting agenda (40 proposals), board slate and governance materials will be mailed to ADS and ordinary shareholders in May 2026.
DBV Technologies reported first quarter 2026 results showing higher spending as it prepares for potential commercialization of its VIASKIN Peanut patch. Net loss widened to $47.6 million from $27.1 million a year earlier as research, sales, and administrative expenses increased sharply.
Research and development expenses rose to $33.4 million, while sales and marketing and general and administrative costs climbed to $4.8 million and $10.5 million, respectively. Despite the larger loss, basic and diluted net loss per share improved from $(0.26) to $(0.11) due to a strengthened equity base.
DBV ended March 31, 2026 with $229 million in cash and cash equivalents, up from $194 million at year-end 2025, supported by $89 million of financing cash flows from warrant exercises. Management currently expects this cash to fund operations into the second quarter of 2027.
DBV Technologies S.A. reported a larger net loss as it ramps up development and commercial preparation for its Viaskin Peanut patch. For the three months ended March 31, 2026, net loss widened to $47.6 million from $27.1 million a year earlier, driven by a sharp increase in operating expenses.
Research and development spending rose to $33.4 million, sales and marketing to $4.8 million, and general and administrative costs to $10.5 million, reflecting expanded clinical activity, pre-commercial inventory build, and build‑out of U.S. commercial and corporate infrastructure. There was still no product revenue; operating income of $0.9 million came mainly from the French research tax credit.
Following a 2025 PIPE financing and warrant exercises, DBV ended the quarter with $229.2 million in cash and cash equivalents, up from $194.2 million at year‑end 2025. Management estimates this cash should fund operations into the second quarter of 2027, assuming current plans focused on Viaskin Peanut, although faster spending or new programs could shorten that runway.
DBV Technologies S.A. files an amended annual report to add detailed Part III disclosures on governance, executive compensation, ownership and related-party transactions. The filing describes a 10‑member board with nine directors independent under Nasdaq rules and gender balance requirements under French law.
As of April 15, 2026, DBV had 296,042,447 ordinary shares outstanding and a public float valued at $250.9 million as of June 30, 2025. The company reports 2025 CEO compensation of $3.36 million, including salary, bonus and equity awards, and outlines its performance‑based pay philosophy and severance terms.
The document also details equity plans with 17.8 million awards outstanding and 17.7 million shares available, large April 2025 PIPE financing generating $125.5 million plus $195.2 million from January 2026 warrant exercises, and the holdings of major shareholders such as Baker Bros., Suvretta, MPM BioImpact and Janus.
DBV Technologies S.A. director Philina Lee filed an initial Form 3, which is a required statement of her beneficial ownership as an insider of the company. The filing shows no reportable transactions in the company’s securities at this time.
DBV Technologies reported full-year 2025 results showing continued investment ahead of a potential launch of its VIASKIN® Peanut Patch. Under U.S. GAAP, operating income was $5.6 million for the year ended December 31, 2025, up from $4.2 million in 2024, mainly from higher French research tax credits.
Research and development expenses rose to $116.7 million, while general and administrative expenses increased to $32.8 million, reflecting clinical progress and launch preparation. Net loss widened to $147.0 million versus $113.9 million in 2024, though net loss per share improved to $1.05 from $1.17. Including $94 million of warrant-related proceeds received in January 2026, management expects existing cash and cash equivalents to fund operations into the second quarter of 2027, based on current plans focused on the VIASKIN Peanut Patch.